Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Oxley

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Journal of Clinical Pathology|March 2, 2016
Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologistsMurali Varma, Lars Egevad, Ferran Algaba, et al.
BMJ Open|November 9, 2019
Phase II randomised control feasibility trial of a nutrition and physical activity intervention after radical prostatectomy for prostate cancerLucy E Hackshaw-McGeagh, Chris Penfold, Ellie Shingler, et al.
The Lancet. Oncology|March 27, 2025
Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trialEoin Dinneen, Ricardo Almeida-Magana, Tarek Al-Hammouri, et al.
Trials|July 22, 2022
NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancerEoin Dinneen, Jack Grierson, Ricardo Almeida-Magana, et al.
The New England Journal of Medicine|September 15, 2016
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
BJU International|January 5, 2020
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progressionRichard J Bryant, Jon Oxley, Grace J Young, et al.
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
JAMA|April 6, 2024
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical TrialRichard M Martin, Emma L Turner, Grace J Young, et al.
Virchows Archiv : an International Journal of Pathology|June 17, 2020
Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted gradingLars Egevad, Daniela Swanberg, Brett Delahunt, et al.
Pathology|December 18, 2019
Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be gradedHemamali Samaratunga, Brett Delahunt, Lars Egevad, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Journal of Clinical Pathology|March 2, 2016
Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologistsMurali Varma, Lars Egevad, Ferran Algaba, et al.
BMJ Open|November 9, 2019
Phase II randomised control feasibility trial of a nutrition and physical activity intervention after radical prostatectomy for prostate cancerLucy E Hackshaw-McGeagh, Chris Penfold, Ellie Shingler, et al.
The Lancet. Oncology|March 27, 2025
Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trialEoin Dinneen, Ricardo Almeida-Magana, Tarek Al-Hammouri, et al.
Trials|July 22, 2022
NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancerEoin Dinneen, Jack Grierson, Ricardo Almeida-Magana, et al.
The New England Journal of Medicine|September 15, 2016
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
BJU International|January 5, 2020
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progressionRichard J Bryant, Jon Oxley, Grace J Young, et al.
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
JAMA|April 6, 2024
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical TrialRichard M Martin, Emma L Turner, Grace J Young, et al.
Virchows Archiv : an International Journal of Pathology|June 17, 2020
Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted gradingLars Egevad, Daniela Swanberg, Brett Delahunt, et al.
Pathology|December 18, 2019
Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be gradedHemamali Samaratunga, Brett Delahunt, Lars Egevad, et al.
Pageof 7